Headache

The European Commission ( EC ) has approved Rinvoq ( Upadacitinib, 15 mg ), an oral, once daily selective and...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus...


The Food and Drug Administration ( FDA ) has approved Xalkori ( Crizotinib ) for pediatric patients 1 year of...


The U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric...


The FDA ( U.S. Food and Drug Administration ) has issued an emergency use authorization ( EUA ) for the...


EMA’s safety committee, PRAC, has concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19...


The FDA ( U.S. Food and Drug Administration ) has approved Abecma ( Idecabtagene vicleucel; Ide-cel ) as the first...


EMA’s safety committee ( PRAC ) has concluded that a warning about unusual blood clots with low blood platelets should...


The FDA ( U.S. Food and Drug Administration ) has expanded the emergency use authorization ( EUA ) for the...


Results from two pivotal phase 3 trials evaluating Deucravacitinib, an oral, selective tyrosine kinase 2 ( TYK2 ) inhibitor, for...


EMA’s human medicines committee ( CHMP ) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty (...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...


The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA...


Safety and final efficacy results from the pivotal phase 3 trial of BNT162b2, the mRNA-based COVID-19 vaccine candidate, were published...


The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of...


The U.S. Food and Drug Administration ( FDA ) has issued an emergency use authorization ( EUA ) for the...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech...


The safety of Comirnaty was evaluated in participants 16 years of age and older in 2 clinical studies that included...


The phase 3 ADVANCE trial evaluating the investigational medicine Atogepant, an orally administered calcitonin gene-related peptide ( CGRP ) receptor...


A study has assessed the effectiveness, safety, and tolerability of Erenumab ( Aimovig ) in a real-life migraine population, while...